San Francisco, December 14, 2020: ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the Equipment Commissioning and Qualification (C&Q) process (validation life cycle) at Biocon Biologics has been digitized leveraging the power of ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system. Biocon Biologics, a subsidiary of Biocon, is an integrated ‘pure play’ biosimilars organization addressing patients’ needs across the world, including developed markets like the U.S., Canada, EU and Australia, through its partners.
The first milestone in the journey has been achieved by ValGenesis and the new system will significantly enhance compliance and increase efficiency in the validation process.
“We are excited at the immense possibilities for growth with Biocon Biologics. With ValGenesis VLMS, the company has a unique opportunity to examine and optimize their validation processes to maximize effectiveness and compliance. The scalable and configurable nature of ValGenesis VLMS will enable Biocon Biologics’ quality leaders to monitor the validation status of their instruments, equipment, software systems, and processes remotely and in real time across multiple sites. We are pleased to help accelerate this iconic company’s digital transformation journey that it had embarked on to meet new millennium opportunities,” says Dr. Siva Samy, CEO & Chief Product Strategist of ValGenesis, Inc.
“ValGenesis is honored to work with Biocon Biologics, a highly reputed and widely recognized fully integrated ‘pure play’ biosimilars organization. With ValGenesis VLMS, Biocon Biologics is now empowered to enable better workforce utilization and optimize their validation processes, resulting in validation management activities becoming more seamless and efficient to better meet the demands of their stakeholders. We are excited about our journey ahead as we work together on innovative digital validation solutions of the future,” says Narayan Raj, Sr. Vice President of Global Sales & Operations at ValGenesis, Inc.
“Quality and Process Excellence drive our operations at Biocon Biologics. The implementation of ValGenesis’s digitized Validation Lifecycle Management System (VLMS) is part of our digital transformation journey and will bring in a high degree of seamless control over our complex validation processes. It will also enable remote and continuous monitoring across multiple facilities. As a part of our commitment to continuous innovation, we are looking at a seamless integration of ValGenesis VLMS to our operations, and are glad to partner with ValGenesis,” says Thibaud Du Merle, Sr. Vice President and Chief Quality Officer at Biocon Biologics.